Page 72 - Read Online

Page 16 of 16 Karolak et al. J Cancer Metastasis Treat 2021;7:15 https://dx.doi.org/10.20517/2394-4722.2021.05

54. Grinshtein N, Rioseco CC, Marcellus R, et al. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that
target glioblastoma brain tumor-initiating cells. Oncotarget 2016;7:59360-76. DOI PubMed PMC
55. Harding T, Swanson J, Van Ness B. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial
transcriptomic changes. Oncotarget 2018;9:21930-42. DOI PubMed PMC
56. Huang JP, Ling K. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially
27
increasing H3 Lys acetylation in the. BIM ;14:5735-42. DOI PubMed PMC
57. Takashina T, Kinoshita I, Kikuchi J, et al. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for
non-small-cell lung cancer cells. Cancer Sci 2016;107:955-62. DOI PubMed PMC
58. Lindsay H, Kogiso M, Qi L, et al. AT-01 Therapeutic targeting of INI1 deficiency in pediatric atrt: A pre-clinical study utilizing
patient derived orthotopic xenograft (PDOX) models. Neuro-Oncology 2015; ;17:iii1.
59. Zhang A, Piunti A, Ozark P, et al. ATRT-02 Therapeutic targeting of EZH2 and BET BRD4 in AT/RT. Neuro-Oncology 2019;21:ii63.
60. Stacchiotti S, Schoffski P, Jones R, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with
epithelioid sarcoma (ES) (NCT02601950). JCO 2019;37:11003.
61. Stacchiotti S, Zuco V, Tortoreto M, et al. Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance
Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. Cancers (Basel)
2019;11:1015. DOI PubMed PMC
62. Zhang P, Yang X, Ma X, et al. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor
through the miR-30a and KPNB1 pathway. Mol Cancer 2015;14:55. DOI PubMed PMC
63. Fourneaux B, Bourdon A, Dadone B, et al. Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role
to overcome secondary resistance to PI3K/mTOR inhibition. J Hematol Oncol 2019;12:11. DOI PubMed PMC
64. Velez AM, Okada T, Singer S. Aberrant expression of epigenetic modifiers in dedifferentiated liposarcoma (DDLS) and the effects of
dual inhibition of DNA and histone methylation in DDLS cell lines. Abstract Book: Society of Surgical Oncology 69th Annual Cancer
Symposium. Ann Surg Oncol 2016:23,S37-8. DOI
65. Wen Y, Cai J, Hou Y, Huang Z, Wang Z. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Oncotarget 2017;8:37974-90. DOI PubMed PMC
66. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
Science 2012;338:1465-9. DOI PubMed PMC
67. Lee ST, Li Z, Wu Z, et al. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell
2011;43:798-810. DOI PubMed
68. Jung HY, Jun S, Lee M, et al. PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation. Mol Cell 2013;52:193-205. DOI
PubMed PMC
69. Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer
cells. Mol Cell Biol 2007;27:5105-19. DOI PubMed PMC
70. Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes
tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013;23:839-52. DOI PubMed PMC
71. Wang X, Brea LT, Yu J. Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer
immunotherapy. Am J Clin Exp Urol 2019;7:85-91. PubMed PMC
72. Raj S, Miller LD, Triozzi PL. Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy.
Sarcoma 2018;2018:9305294. DOI PubMed PMC
73. Christofides A, Karantanos T, Bardhan K, Boussiotis VA. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Oncotarget 2016;7:85624-40. DOI PubMed PMC
74. Carlo V, Mocavini I, Di Croce L. Polycomb complexes in normal and malignant hematopoiesis. J Cell Biol 2019;218:55-69. DOI
PubMed PMC
75. Karantanos T, Chistofides A, Barhdan K, Li L, Boussiotis VA. Regulation of T Cell Differentiation and Function by EZH2. Front
Immunol 2016;7:172. DOI PubMed PMC
76. Stairiker CJ, Thomas GD, Salek-Ardakani S. EZH2 as a Regulator of CD8+ T Cell Fate and Function. Front Immunol
2020;11:593203. DOI PubMed PMC
77. Herviou L, Cavalli G, Cartron G, Klein B, Moreaux J. EZH2 in normal hematopoiesis and hematological malignancies. Oncotarget
2016;7:2284-96. DOI PubMed PMC
78. Li B, Chng WJ. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. J Hematol
Oncol 2019;12:118. DOI PubMed PMC
79. Huang S, Wang Z, Zhou J, et al. EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived
Suppressor Cells. Cancer Res 2019;79:2009-20. DOI PubMed
80. Goswami S, Apostolou I, Zhang J, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin
Invest 2018;128:3813-8. DOI PubMed PMC
81. Xiao G, Jin LL, Liu CQ, et al. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer
2019;7:300. DOI PubMed PMC
82. Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not
silenced by DNA methylation. Mol Cancer Ther 2009;8:1579-88. DOI PubMed PMC